Back

The serum haemoglobin to creatinine ratio predicts 1-year adverse outcomes in patients undergoing transcatheter aortic valve implantation

26 August 2023 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Old and new predictors of outcome after TAVI Aortic Valve Stenosis ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Akihiro Ikuta

Kurashiki Central Hospital, Kurashiki (Japan)

5 More presentations in this session

Presentation thumbnail
5-year outcome comparison among aortic stenosis patients underwent transcatheter aortic valve implantation with or without permanent pacemaker
Doctor K. Hu (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Reduction in systolic pulmonary artery pressure after TAVI is associated with lower cardiovascular mortality in patients with severe aortic stenosis
Doctor D. Liu (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Impact of pre-procedural bioprosthetic leaflet calcification on hemodynamic and hlinical outcomes after aortic valve-in-valve procedure.
Mr R. Carter-Storch (Odense, DK)
Abstract Slides Video
Presentation thumbnail
Real-world outcome and long-term survival analysis after trans-catheter aortic valve implantation (TAVI) - does age matter?
Professor M. Franz (Rotenburg an der Fulda, DE)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes after transcatheter aortic valve implantation in patients older than 90 years of age.
Doctor N. Ehara (Kobe, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Old and new predictors of outcome after TAVI

The Event

Event poster

ESC Congress 2023

26 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Hemoglobin/creatinine ratio predicts mortality in hospitalized patients for acute heart failure with reduced ejection fraction
thumbnail
Congress Session
Improving prognosis after TAVI
thumbnail
Congress Presentation
Hemoglobin/creatinine ratio as long- term prognostic marker in acute coronary syndromes: a praise registry study.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources